Volume : 08, Issue : 11, November – 2021



Authors :

Prabhat Tiwari, Dr. Alok Pal Jain, Vivek Shrivastava

Abstract :

A novel stability-indicating RP-HPLC method has been developed and validated for quantitative analysis of Emtricitabine in the bulk drug and in a pharmaceutical dosage form. An isocratic separation of EMT was achieved on Thermo C18 column (4.6 x 250mm, 5 μ particle size) as the stationary phase with a flow rate of 1 ml/min and using a UV detector to monitor the eluate at 254 nm. The mobile phase consisted of Acetonitrile: methanol (50:50v/v) enabled separation of the drug from its degradation products. The method was validated for linearity, accuracy (recovery), precision, specificity, and robustness. Linearity was established by least squares linear regression analysis of the calibration curve. The calibration curve was linear over the concentration range of 5-25μg/ml and correlation coefficients were found to be 0.999 for Emtricitabine respectively. Recovery studies were carried out by applying the method to drug sample to which known amount of Emtricitabine at three concentration levels of 80, 100% and120 % were added. At each level %recovery was determined, which are in the range of 98.67±0.406- 99.00±0.030%. The precision of the analytical method was studied by multiple sampling of the homogenous sample. The precision was done by measuring the absorbance for six times. The % RSD value was found to be 0.767, 1.224, 1.870 for repeatability, day to day and analyst to analyst respectively indicating that the method is precise. The forced degradation study prove the stability indicating power of the method and therefore, the validated method may be useful for routine analysis of Emtricitabine as bulk drug, in respective dosage forms, for dissolution studies and as stability indicating assay method in pharmaceutical laboratories and industries.
Keywords: RP-HPLC, Emtricitabine, Forced degradation, Method validation, repeatability

Cite This Article:

Please cite this article in press Prabhat Tiwari et al, New HPLC Method Development And Validation For The Estimation Of Emtricitabine In Marketed Formulation., Indo Am. J. P. Sci, 2021; 08(11).

Number of Downloads : 10


1. Sethi P.D.; HPLC: Quantitative Analysis of Pharmaceutical Formulation; CBS Publishers and Distributors, New Delhi; 1996;113-202.
2. Davidson A.G., Beckett A.H. and Stenlake J.B.; Practical Pharmaceutical Chemistry; 4th edition; CBS Publishers and Distributors, New Delhi; 1989; 276- 99.
3. Jeffery G.H., Bassett J., Mendham J. and Denrey R.C.; Vogel’s Textbook of Quantitative Chemical Analysis; 5th edition; Longman Group UK Ltd, England; 1989; 6-14.
4. http,//wwwyoungincom/application/AN-0608-0115ENpdf.
5. Swarbrick, James B. and James. C.; Encyclopedia of pharmaceutical technology; Volume I; Marcel Dekker Inc., New York; 1998; 217 -224.
6. Sahu R. Nagar P. and Jain D.; Indian J. Pharm. Science; 2006; 68(4);503-506.
7. Jain N., Jain R., Swami H. and Pandey S.; Indian Journal of Pharmacy and Pharmaceutical sciences,2009, 1(1),189-191.
8. Khan, M.R. and Jain, D.; Indian Journal of Pharmaceutical sciences; 2006;64(6);546-548.
9. Meyer Veronica R.; Practical High Performance Liquid Chromatography; 2ndedition, John wiley and sons,London;1993;56-58.
10. Braumann T., Weber G. and Grimme L.H.; J.Chromatogr;1983;48-65.
11. Snyder L.R.; Dolan J.W. and Dolan J.W.; J.Chromatogr; 1989;48-65.
12. Aitzemuller K.; Practice of High Performance Liquid Chromatography,springer–Verlag; 1986; 301.
13. SGE International Pty. Ltd, TA-0010-H,2001.
14. FDA; Draft Guidance for Industry, Stability Testing of Drug Substances and Drug Products; (FDA, Rockville, MD, June 1998);glossary.
15. ICH; Guidance for Industry, Q1A(R2); Stability Testing of New Drug Substances and Products; November; 2003;1-17.
16. European Council (1993) Directive 93/42/EEC of 14 June1993.
17. European Council (1990) Directive 90/385/EEC of 20 June 1990 on active implantable medicaldevices.
18. Dan W., Reynolds Kevin L., Facchine June F. and Mullaney; Conducting Forced Degradation Studies; Pharmaceutical Technology;2002.
19. FDA; ICH: Guideline on the Validation of Analytical Procedures: Methodology, Availability, Notice; Federal Register 62 (96); 19 May 1997;27463–27467.
20. Conners K.A., G.L. Amidon, and Stella, V.L.; Chemical Stability of Pharmaceuticals; Wiley and Sons; New York; 2d Ed.; 1986;375-384.
21. FDA; ICH: Guideline for the Photostability Testing of New Drug Substances and New Drug Products; ICH Q1B; Federal Register 62 (95); 16 May 1997; 27115–27122 .
22. FDA; Center for Drug Evaluation and Research; Submitting Documentation for the Stability of Human Drugs and Biologics; Rockville, MD; February 1987;38.
23. FDA; ICH: Guideline on Impurities in New Drug Products; ICH Q3B; Federal Register (Notices); 62 (96); 19 May 1997;27453–274561.
24. FDA; Draft Guidance for Industry, Stability Testing of Drug Substances and Drug Products FDA, Rockville, MD, June 1998;glossary.
25. FDA; ICH: Guidance on Q6A Specifications; ICHQ6A; Federal Register (Notices); 65 (251); 29 December 2000;83041–83063.
26. Reynolds, DW; Forced degradation of pharmaceuticals; Am Pharm Rev 2004; 56–61.
27. Dolan J.W.; Stability-indicating assays; LCGC N Am; 2002; 20;346–349.
28. Ruan J., Tattersall P., Lozano R. and Shah; The role of forced degradation studies in stability indicating HPLC method development; Am Pharm Rev 2006; 946–53.
29. Wen C.; Designing HPLC methods for stability indication and forced degradation samples for API; Am Pharm Rev 9; 2006; 137–140.
30. Baertschi S.W. and Boccardi G.; Oxidative susceptibility testing. In: Baertschi SW(ed) Pharmaceutical stress testing: predicting drug degradation; Taylor & Francis, Boca Raton;2005.